Navigation Links
Ferring Pharmaceuticals Announces Immediate Availability of Degarelix for the Treatment of Advanced Prostate Cancer
Date:3/4/2009

New Drug Provides Rapid and Sustained Suppression of Testosterone

PARSIPPANY, N.J., March 4 /PRNewswire/ -- Ferring Pharmaceuticals, USA today announced the U.S. commercial availability of degarelix for injection (trade name pending), a new injectable gonadotropin-releasing hormone (GnRH) receptor antagonist approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone sensitive advanced prostate cancer. Degarelix is available for order through traditional and specialty pharmacy distributors.

Degarelix provides fast, long-term suppression of testosterone, a hormone that stimulates prostate cancer growth.(1-3) Clinical trials demonstrated that degarelix is effective in quickly reducing and sustaining castrate levels of testosterone.(2,3) Degarelix works differently than a luteinizing hormone-releasing hormone (LHRH) agonist by binding immediately and reversibly to GnRH receptors in the pituitary gland, quickly reducing the release of gonadotropins and consequently testosterone. In the Phase III study vs. leuprolide, the degarelix group achieved a 90 percent decrease in median testosterone levels at Day 3 of treatment, compared with the leuprolide group, which experienced a 65 percent increase in median testosterone levels. By Day 3, 96 percent of degarelix patients achieved castrate levels of testosterone, compared with zero percent receiving leuprolide. In addition, degarelix was as effective as leuprolide in suppressing testosterone levels from Day 28 to the end of the study (Day 364), with 97.2 percent of the degarelix patients maintaining medical castrate levels compared with 96.4 percent for leuprolide.

Study findings also showed that prostate specific antigen (PSA) levels were lowered by 64 percent two weeks after administration of degarelix, 85 percent after one month, 95 percent after three months, and remained suppressed throughout the one year of treatment.(1,2)
'/>"/>

SOURCE Ferring Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Ferring Pharmaceuticals Promotes William Garbarini to Vice President of New Orthopaedics and Urology Business Unit
2. Dr. Jan Linhart Now Offerring Unique Laser Teeth Whitening System
3. Ferring Pharmaceuticals EUFLEXXA(R) to Serve as a Sponsor for the Babolat World Tennis Classic
4. Increase in Diagnostic Imaging Fueled by Self-Referring Doctors
5. Ferring Pharmaceuticals EUFLEXXA(TM) to Serve as Sponsor for Sprint Force America Masters Track Club
6. Ferring Announces $10,000 Grand Prize Winner of 2007 My Little Miracle Essay Contest
7. Frost & Sullivan Lauds OVATION Pharmaceuticals for Its Business Model and Ability to Sustain Growth
8. NovaBay Pharmaceuticals Announces New Preclinical Data to be Presented at the American Academy of Dermatology (AAD) 67th Annual Meeting
9. Levels of Trace Pharmaceuticals in Drinking Water Too Low to Impact Human Health According to Water Research Foundation Study
10. AUDIO from Medialink and Ortho-McNeil-Janssen Pharmaceuticals: Risks of Overusing Antibiotics
11. Onyx Pharmaceuticals to Present at the Barclays Capital Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... December 26, 2014 The report ... to 2023” focuses on the current treatment landscape, ... the colorectal cancer market. Stivarga is a drug ... or rectal cancer. Boehringer Ingelheim is developing nintedanib ... treatment of refractory CRC in the US, Europe, ...
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 The ... to 2023” focuses on the current treatment landscape, unmet ... cancer market. TS-1 is an anti-cancer drug which is ... orally and is also used for treating gastric cancer ... and otastat potassium. The drug was first approved in ...
(Date:12/25/2014)... York, New York (PRWEB) December 25, 2014 ... the 2010 DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) ... LLP reports. According to an Order issued in the ... 20th, the Court will convene an open conference on ... Building and United States Courthouse in West Palm Beach, ...
(Date:12/25/2014)... months the trends for evening dresses shift and ... of the hottest styles in the next few months.” The ... 26 A-line sweetheart evening dresses, and announces the availability of ... trying our best to help a lady to show off ... prices, we provide discounted delivery costs to our customers worldwide. ...
(Date:12/25/2014)... Recently, iFitDress.com, the popular online supplier of wedding dresses and ... of black one-shoulder cocktail dresses . In addition, all ... at discounted prices, up to 70% off. , ... weeks only. You know, we have thousands of frequent callers ... new items can visit our website for more details. The ...
Breaking Medicine News(10 mins):Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2
... a motive of enabling women the best possible avenues to ... free breast cancer screening// in Dubai, scheduled to begin next ... in the emirate, UAE nationals, expatriates and visitors, to avail ... is absolutely essential to achieve better treatment outcomes. ...
... leaders in Wales are calling on the National Assembly for ... and release// patients from a heavy financial burden. ... people to park at hospitals is an indirect tax on ... hospital clinics do so by car. Often, these people have ...
... Anti-retrovirals have always been a blessing for the HIV patients, ... double blessing; ARV’s are capable of halting// the progress of ... is well known that HIV-infection could lead to mental illness. ... to HIV. Dr Michelle Rogers, a psychiatrist, says: "There were ...
... from Bristol University has developed a technique, using luciferase, to ... in detecting// damage to heart cells after a heart attack. ... for rapid recovery from cardiac arrests and heart surgery. This ... of Biological Chemistry. ,Dr Elinor Griffiths and her ...
... published the findings of the head to head trial of ... The study was an effort in drawing a methodical comparison ... ED and diabetes, hypertension, and/or hyperlipidemia. The results showed that ... use of this drug. ,A total of 1,057 ...
... records in paper form and scattered across the offices ... need those records// most--when you're lying on a gurney ... to do. Sometimes they do the wrong thing: in ... from medical mistakes, and 1.5 million people suffer from ...
Cached Medicine News:Health News:Abolish Car Parking Charges at Welsh Hospitals, says BMA Cymru Wales 2Health News:Abolish Car Parking Charges at Welsh Hospitals, says BMA Cymru Wales 3Health News:Abolish Car Parking Charges at Welsh Hospitals, says BMA Cymru Wales 4Health News:A glowing energy measure for heart cells 2Health News:Patients suffering ED happy with Vardenafil drugs 2Health News:Dying for Data 2
(Date:12/24/2014)... , Dec. 24, 2014  Actavis plc (NYSE: ... Company has received a complete response letter from ... its New Drug Application (NDA) for the fixed-dose ... treatment of hypertension.   Photo - ... disappointed in the receipt of a complete response ...
(Date:12/24/2014)... 24, 2014 Soligenix, Inc. (OTCQB: SNGX) ... developing products that address unmet medical needs in ... today that on December 24, 2014 it closed ... The Company raised approximately $2.3 million in gross ... the net proceeds from the offering to fund ...
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, 2014 ... a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics ... medical need and commercial potential, today announced that ... 2,050,000 shares of its common stock and Series ... common stock.  Funds under the management of QVT ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4Soligenix Announces Closing of Public Offering of Units 2Soligenix Announces Closing of Public Offering of Units 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
This model of bench top refrigerated incubator has been designed to suit the TPS-32 platelet shaker....
ELISA for detection of Anti-Gliadin IgG....
An enzyme-linked immuno-sorbent assay for the detection and quantitation of anti-tissue Transglutaminase in serum of patients with Celiac Disease and Dermatitis Herpetiformis....
Enzyme immunoassay for the quantitative determination of Gliadin-IgG antibodies in serum and plasma. This kit provides specific determination of gliadin antibodies by using highly purified gliadin....
Medicine Products: